Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-06-05
2007-06-05
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C536S024330, C435S006120, C435S091100, C435S325000, C435S375000
Reexamination Certificate
active
09923515
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for treatment of diseases associated with expression of apolipoprotein(a) are provided.
REFERENCES:
patent: 5721138 (1998-02-01), Lawn
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5866551 (1999-02-01), Benoit et al.
patent: 6008344 (1999-12-01), Bennett et al.
patent: 6080580 (2000-06-01), Baker et al.
patent: 6512161 (2003-01-01), Rouy et al.
patent: 6573050 (2003-06-01), Ben-David et al.
patent: 6613567 (2003-09-01), Bennett et al.
patent: 6809193 (2004-10-01), McKay et al.
patent: WO 96/09392 (1996-03-01), None
patent: WO 99/35241 (1999-01-01), None
patent: WO 99/35241 (1999-07-01), None
patent: WO-03/014307 (2003-02-01), None
patent: WO 03/014307 (2003-02-01), None
patent: WO-2005/000201 (2005-01-01), None
Fritz et al. Cationic Polystyrene Nonoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides. Journal of Colloid and Interface Science, 1997; 195:272-288.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells, 2000, vol. 18:307-319.
Dias et al. Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics, 2002 vol. 54:263-269.
McLean et al. cDNA sequence of human apolipoprotein (a) is homogolous to plasminogen. Nature, 1987 vol. 330:132-137.
Hajjar et al. The role of lipoprotein (a) in atherogenesis and thrombosis. Annual Review in Medicine, 1996 vol. 47:423-442.
Morishita et al. Novel Therapeutic Strategy for Atherosclerosis. Circulation, 1998 vol. 98 :1898-1904.
McLean et al. cDNA sequence of human apolopoprotein (a) is homologous to plasminogen. Nature, 1987 vol. 330:132-137.
Prosnyak et al. Substitution of 2-Aminoadenine and 5-Methylcytosine for Adenine and Cytosine in Hybridization Probes Increasees the Sensitivity of DNA Fingerprinting. Genomics, 1994 vol. 21:490-494.
Deverre et al. A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides. Nucleic Acids Research 1997 vol. 25:3584-3589.
Skerra, A. Phosphorothioate primers imprive the amplification of DNA sequences by DNA polymerase with proofreading activity. Nucleic Acids Research, 1992 vol. 20:3551-3554.
Frank et al., “The apolipoprotein (a) gene residues on human chomosome 6q26-27, in close proximity to the homologous gene for plasminogen”,Hum. Genet1988 79:352-356.
Grainger et al., “Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice”,Nature1994 370:460-462.
Hajjar et al., “The role of Lipoprotein(a) in Atherogenesis and Thrombosis”,Annu. Rev. Med.1996 47:423-442.
Katan et al., “Characteristics of Human Hypo-And Hyperresponders to Dietary Cholesterol”,Am. J. of Epidemiology1987 125 (3):387-399.
Lawn et al., “Atherogenesis in transgenic mice expressing human apolipoprotein(a)”,Nature1992 360:670-672.
McLean et al., “cDNA sequence of human apolipoprotein(a) is homologous to plasminogen”,Nature1987 330:132-137.
Morishita et al., “Novel Therapeutic Strategy for Atherosclerosis—Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression”,Basic Science Reports1998 1898-1904.
Nowak-Göttl et al., “Lipoprotein (a): Its Role in Childhood Thromboembolism”,Pediatrics1997 99 (6):1-3.
Rainwater et al., “Lipoprotein Lp(a) :Effects of Allelic Variation at the LPA Locus”,J. Exp. Zoology1998 282:54-61.
Sandkamp et al., “Lipoprotein(a) Is an Independent Risk Factor for Myocardial Infarction at a Young Age”,Clin. Chem.1990 36(1):20-23.
Seed et al., “Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia”,New. England J. of Medicine1990 1494-1499.
Vessby et al., “Diverging Effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp(a)”,Atherosclerosis1982 44:61-71.
Ohmichi et al., “The virtues of self-binding: high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes” Nuc. Acid. Res. Feb. 1, 2000 28(3):776-783.
Callow et al., “Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice”,Proc. Natl. Acad. Sci. USA, Mar. 1994, 91: 2130-2134.
Green et al., “Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease”,J. Am. Coll. Surg.Jul. 2000 191 (1):93-105.
Opalinska et al., “Nucleic-acid therapeutics: Basic principles and recent applications”,Nat. Rev.Jul. 2002 1(7): 503-514.
Anderson, et al., “A Comparison of Selected mRNA and Protein Abundances in Human Liver.”Electrophoresis. 18:533-537. 1997.
U.S. Appl. No. 60/475,402, filed Jun. 2, 2003 by Crooke, et al.
Office Action dated Aug. 26, 2005 that issued in U.S. Appl. No. 10/684,440, filed Oct. 15, 2003 by Crooke, et al.
International Search Report from PCT/US2004/014540 dated Jan. 25, 2006.
Agrawal, et al., TIBTECH 1996. 14:376-387.
Braasch, D.A., Biochemistry. Apr. 2002; 41(14): 4503-4510.
Gowirtz et al., Proc. Natl. Acad. Sci. 1996, v 93, pp. 3181-3183.
Tamm, I. et al. The Lancet. Aug. 2001, 358: 489-497.
K. Kostner et al, “Lipoprotein (a): Still an enigma?”, Current Opinion in Lipidology, 13:391-396 (Aug. 2002).
H. Weintraub, “Antisense RNA and DNA”, Scientific American, pp. 40-46 (Jan. 1990).
J. Milligan et al, “Current Concepts in Antisense Drug Design”, J. Medicinal Chemistry, 36(14):1923-1927 (Jul. 1993).
S. Frank, et al, “Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo”, Gene Therapy 8(6):425-430 (Mar. 2001).
Crooke Rosanne M.
Graham Mark J.
Gibbs Terra C.
Isis Pharmaceuticals , Inc.
Knobbe Martens Olson and Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of apolipoprotein (a) expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of apolipoprotein (a) expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of apolipoprotein (a) expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863211